# EDGAR Filing Document

**Accession Number:** 0001758530
**File Stem:** 0001104659-26-034066
**Filing Date:** 2026-3
**Character Count:** 43179
**Document Hash:** b745655035d4016ae648c8416ba8ce13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-034066.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001104659-26-034066

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260325

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** So-Young International Inc.
- **CENTRAL INDEX KEY:** 0001758530
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38878
- **FILM NUMBER:** 26788252

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2/F, EAST TOWER, POLY PLAZA
- **STREET 2:** NO. 66 XIANGBIN ROAD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **PROVINCE COUNTRY:** F4
- **ZIP:** 100012
- **BUSINESS PHONE:** 00861087902012

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2/F, EAST TOWER, POLY PLAZA
- **STREET 2:** NO. 66 XIANGBIN ROAD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **PROVINCE COUNTRY:** F4
- **ZIP:** 100012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2026

Commission File Number: 001-38878

**So-Young International Inc.**

2/F, East Tower, Poly Plaza

No. 66 Xiangbin Road

Chaoyang District, Beijing, 100012

People's Republic of China

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

<u>Exhibit Index</u>

[Exhibit 99.1—Press Release](tm269793d1_ex99-1.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **So-Young International Inc.** | **So-Young International Inc.** | **So-Young International Inc.** |
| By | : | /s/ Xing Jin |
| Name | : | Xing Jin |
| Title | : | Chief Executive Officer |

---

Date: March 25, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](tm269793d1_ex99-1img001.jpg)

**So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results**

BEIJING, China, Mar. 25, 2026 — So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.

**Fourth Quarter 2025 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Total
 revenues were RMB460.7 million (US$65.9 million <sup>1</sup>),
 compared with RMB369.2 million in the corresponding period of 2024. The aesthetic treatment
 services revenues were RMB248.1 million (US$35.5 million), compared with RMB81.3 million
 in the corresponding period of 2024, exceeding the high end of guidance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Net
 loss attributable to So-Young International Inc. was RMB108.8 million (US$15.6 million),
 compared with net loss attributable to So-Young International Inc. of RMB607.6 million in
 the same period of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Non-GAAP
 net loss attributable to So-Young International Inc. <sup>2</sup> was RMB93.4 million (US$13.2 million), compared with non-GAAP net loss attributable to So-Young
 International Inc. of RMB53.2 million in the same period of 2024.

**Fourth Quarter 2025 Operational Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The
 number of verified treatment visits to the branded aesthetic centers for the quarter reached
 over 125,000, compared with approximately 45,000 in the same period of 2024. The number of
 verified aesthetic treatments performed surpassed 289,400, compared with approximately 107,900
 in the same period of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The
 number of active users, defined as those who visited branded aesthetic centers at least once
 during the 12-month period ended on December 31, 2025, exceeded 171,000, compared with
 approximately 52,700 users during the corresponding period in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The
 number of core members grew by over 14,500 during the quarter, representing an approximately
 39% sequential increase. Both the revenue contribution from core members to aesthetic treatment
 services and their quarterly repurchase rate exceeded 80%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· As
 of December 31, 2025, So-Young had 49 fully operational branded aesthetic centers (48
 directly-operated, 1 franchised) across fifteen major cities: Beijing, Shanghai, Guangzhou,
 Shenzhen, Hangzhou, Chengdu, Wuhan, Chongqing, Ningbo, Changsha, Tianjin, Xi'an, Suzhou,
 Hefei and Kunming. Among them, 25 centers achieved profitability\* in the fourth quarter. In addition, 39 centers generated positive quarterly
 operating cash flow\* in the fourth quarter. The following table shows the revenues generated
 by So-Young aesthetic centers, categorized by their phase of development:

<sup>1</sup> This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.9931 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on December 31, 2025.

<sup>2</sup> Non-GAAP net income/(loss) attributable to So-Young International Inc. is defined as net income/(loss) attributable to So-Young International Inc. excluding share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Phase\*\* (Operating duration)** | **Number of Centers** | **Revenue (RMB)** | **Average Revenue per Center (RMB)** | **Average Center Age (Month)** |
| Ramp-up (0-3 months) | 13 | 16598000 | 1277000 | 1.2 |
| Growth (4-12 months) | 19 | 88955000 | 4682000 | 7.1 |
| Maturity (over 12 months) | 17 | 142523000 | 8384000 | 17.8 |

---

\* Center-level profitability measures whether an individual aesthetic center achieved positive profit in a given period. It is calculated by deducting consumable materials costs, personnel costs, center rental expenses, center depreciation expenses, and other center-level operating costs from the company's self-operated store revenues, before allocation of any back-office or mid-office expenses. Quarterly operating cash flow refers to total cash collected from orders less center-level operating payments in a given period, and excluding operating expense payments made by back-office or mid-office departments during the same period. Center-level profitability and quarterly operating cash flow are metrics derived from the Company's internal management accounts, which have not been audited.

\*\* For the purposes of this table, "Phase" refers to the length of time since commencement of actual operations rather than the legal establishment or registration date of a branded aesthetic center. In cases where a center has been relocated, merged, or its team and customer base transferred to another location, the operating duration of the branded aesthetic center is calculated from the commencement date of the predecessor center's operations. Periods during which a center is temporarily closed and not conducting external operations (e.g., due to renovation or other suspensions of business) are excluded from the calculation of operating duration. Branded aesthetic centers that have been converted to other uses or are no longer within the reporting scope are excluded from the statistics.

**Fiscal Year 2025 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Total
 revenues were RMB1,523.4 million (US$217.8 million) in fiscal year 2025, compared with RMB1,466.7
 million in the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Net
 loss attributable to So-Young International Inc. was RMB242.3 million (US$34.6 million) in
 fiscal year 2025, compared with a net loss attributable to So-Young International Inc. of
 RMB589.5 million in the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Non-GAAP
 net loss attributable to So-Young International Inc. was RMB217.1 million (US$31.0 million)
 in fiscal year 2025, compared with a non-GAAP net loss attributable to So-Young International
 Inc. of RMB4.7 million in the prior year.

**Extension of Share Repurchase Program**

The share repurchase program, initially approved on March 18, 2024, authorizing the repurchase of up to US$25 million in ADSs or ordinary shares, has been extended for an additional 12-month period through March 31, 2027. In 2024 and 2025, the Company repurchased approximately 4.8 million ADSs. All other terms remain unchanged.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "In the fourth quarter, our aesthetic center business maintained its strong momentum, solidifying its role as a core growth engine for the Group. We have retained our position as China's leading light medical aesthetics chain by scale, which serves as a clear validation of our business model's strength and sustainability. Looking ahead, we will pursue steady store expansion while prioritizing operational excellence and industry-leading standards. Through strategic alliances with upstream manufacturers and a commitment to genuine product traceability, we are building competitive advantages rooted in both unit economics and trust. We are confident that this disciplined approach will drive sustainable value for our shareholders."

**Fourth Quarter 2025 Financial Results**

***Revenues***

Total revenues were RMB460.7 million (US$65.9 million), an increase of 24.8% from RMB369.2 million in the same period of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

· **Aesthetic treatment services** revenues were RMB248.1 million (US$35.5 million), an increase
 of 205.3% from RMB81.3 million in the same period of 2024. The increase was primarily due
 to the business expansion of the branded aesthetic centers.

· **Information and reservation services <sup>3</sup>** revenues were
 RMB125.7 million (US$18.0 million), a decrease of 26.8% from RMB171.6 million in the same
 period of 2024. The decrease was primarily due to a decrease in the number of medical service
 providers subscribing to information services on So-Young's platform.

· **Sales of medical products and maintenance services** revenues were RMB69.3 million (US$9.9 million),
 a decrease of 19.9% from RMB86.4 million in the same period of 2024, primarily due to a decrease
 in the order volume for medical equipment.

· **Other services** revenues were RMB17.7 million (US$2.5 million), a decrease of 40.7% from RMB29.9
 million in the same period of 2024, primarily due to a decrease in revenues from So-Young
 Prime.

***Cost of Revenues***

Cost of revenues was RMB255.9 million (US$36.6 million), an increase of 67.2% from RMB153.1 million in the fourth quarter of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of aesthetic treatment services** was RMB189.0 million (US$27.0 million), an increase of
 189.9% from RMB65.2 million in the fourth quarter of 2024. The increase was primarily due
 to the business expansion of the branded aesthetic centers.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of information and reservation services <sup>4</sup>** was RMB10.1 million (US$1.4 million), a decrease of 50.6% from RMB20.4 million in the fourth
 quarter of 2024. The decrease was in line with the decrease in revenue generated from information
 and reservation services.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of medical products sold and maintenance services** was RMB41.6 million (US$5.9 million),
 a decrease of 4.0% from RMB43.3 million in the fourth quarter of 2024. The decrease was primarily
 due to a decrease in costs associated with the sales of medical equipment.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of other services** was RMB15.3 million (US$2.2 million), a decrease of 36.7% from RMB24.1
 million in the fourth quarter of 2024. The decrease was primarily due to a decrease in costs
 associated with So-Young Prime.

***Operating Expenses***

Total operating expenses were RMB327.7 million (US$46.9 million), a decrease of 59.8% from RMB815.2 million in the fourth quarter of 2024.

· **Sales and marketing** expenses were RMB168.7 million (US$24.1 million), an increase of 25.8%
 from RMB134.0 million in the fourth quarter of 2024. The increase was primarily attributable
 to an increase in expenses associated with branding and user acquisition activities for the
 branded aesthetic centers.

· **General and administrative** expenses were RMB101.9 million (US$14.6 million), an increase
 of 3.5% from RMB98.4 million in the fourth quarter of 2024. The increase was primarily due
 to the business expansion of the branded aesthetic centers.

<sup>3</sup> Since the second quarter of 2025, in light of the better monitoring business development of branded aesthetic centers, the previous line item information, reservation services and others was separated into two line items, which are information and reservation services and other services.

The revenue generated from information and reservation services and other services for the fourth quarter of 2024 have also been retrospectively updated. The amount reclassified from previous line item information, reservation services and others to information and reservation services is RMB171.6 million for the fourth quarter of 2024.

<sup>4</sup> Since the second quarter of 2025, the previous line item cost of information, reservation services and others was separated into two line items, which are cost of information and reservation services and cost of other services. Cost of information and reservation services primarily consists of expenditures relating to operation of platform business, and the remaining cost of information, reservation services and others is reclassified into cost of other services. The cost of information and reservation services and cost of other services for the fourth quarter of 2024 have also been retrospectively reclassified.

· **Research and development** expenses were RMB37.4 million (US$5.4 million), a decrease of 12.4%
 from RMB42.8 million in the fourth quarter of 2024. The decrease was primarily attributable
 to improvements in staff efficiency.

· **Impairment of goodwill and long-lived assets** was RMB19.7 million (US$2.8 million) in this quarter,
 representing the amount by which the carrying amount of certain asset exceeds their fair
 value, based on an annual long-lived assets impairment assessment. Impairment of goodwill
 was RMB540.0 million in the fourth quarter of 2024.

***Income Tax Benefits/(Expenses)***

Income tax benefits were RMB0.6 million (US$0.1 million), compared with income tax expenses of RMB2.1 million in the same period of 2024.

***Net Loss Attributable to So-Young International Inc.***

Net loss attributable to So-Young International Inc. was RMB108.8 million (US$15.6 million), compared with a net loss attributable to So-Young International Inc. of RMB607.6 million in the fourth quarter of 2024.

***Non-GAAP Net Loss Attributable to So-Young International Inc.***

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB93.4 million (US$13.2 million), compared with RMB53.2 million non-GAAP net loss attributable to So-Young International Inc. in the same period of 2024.

***Basic and Diluted Loss per ADS***

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB1.08 (US$0.15) and RMB1.08 (US$0.15), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.92 and RMB5.92, respectively, in the same period of 2024.

**Fiscal Year 2025 Financial Results**

***Revenues***

Total revenues were RMB1,523.4 million (US$217.8 million), an increase of 3.9% from RMB1,466.7 million in fiscal year 2024.

● **Aesthetic treatment services** revenues were RMB674.9 million (US$96.5 million), an increase of 298.7% from RMB169.3 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

● **Information and reservation services** revenues were RMB499.7 million (US$71.5 million), a decrease of 32.2% from RMB736.6 million in fiscal year 2024. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.

● **Sales of medical products and maintenance services** revenues were RMB267.8 million (US$38.3 million), a decrease of 27.2% from RMB368.0 million in fiscal year 2024, primarily due to a decrease in sales of medical equipment.

● **Other services** revenues were RMB81.0 million (US$11.6 million), a decrease of 58.0% from RMB192.8 million in the same period of 2024, primarily due to a decrease in revenues from So-Young Prime.

***Cost of Revenues***

Cost of revenues was RMB795.7 million (US$113.8 million), an increase of 40.2% from RMB567.6 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of aesthetic treatment services** was RMB518.7 million (US$74.2 million), an increase of
 294.2% from RMB131.6 million in fiscal year 2024. The increase was primarily due to the business
 expansion of the branded aesthetic centers.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of information and reservation services** was RMB63.0 million (US$9.0 million), a decrease
 of 41.1% from RMB107.0 million in fiscal year 2024. The decrease was in line with the decrease
 in revenue generated from information and reservation services.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of medical products sold and maintenance services** was RMB147.1 million (US$21.0 million),
 a decrease of 19.7% from RMB183.2 million in fiscal year 2024. The decrease was primarily
 due to a decrease in costs associated with the sales of medical equipment.

&nbsp;&nbsp;&nbsp;&nbsp;· **Cost of other services** was RMB66.9 million (US$9.6 million), a decrease of 54.1% from RMB145.9
 million in fiscal year of 2024. The decrease was primarily due to a decrease in costs associated
 with So-Young Prime.

***Operating Expenses***

Total operating expenses were RMB1,013.9 million (US$145.0 million), a decrease of 33.5% from RMB1,523.6 million in fiscal year 2024.

● **Sales and marketing** expenses were RMB528.6 million (US$75.6 million), an increase of 6.9% from RMB494.5 million in fiscal year 2024. The increase was primarily attributable to an increase in expenses associated with branding and user acquisition activities for the branded aesthetic centers.

● **General and administrative** expenses were RMB328.5 million (US$47.0 million), an increase of 1.4% from RMB324.1 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

● **Research and development** expenses were RMB137.0 million (US$19.6 million), a decrease of 17.0% from RMB165.0 million in fiscal year 2024. The decrease was primarily attributable to improvements in staff efficiency.

● **Impairment of goodwill and long-lived assets** was RMB19.7 million (US$2.8 million) in this year, representing the amount by which the carrying amount of certain asset exceeds their fair value, based on an annual long-lived assets impairment assessment. Impairment of goodwill was RMB540.0 million in fiscal year 2024.

***Income Tax (Expenses)/Benefits***

Income tax expenses were RMB0.8 million (US$0.1 million), compared with an income tax benefits of RMB0.9 million in fiscal year 2024.

***Net Loss Attributable to So-Young International Inc.***

Net loss attributable to So-Young International Inc. was RMB242.3 million (US$34.6 million), compared with a net loss attributable to So-Young International Inc. of RMB589.5 million in fiscal year 2024.

***Non-GAAP Net Loss Attributable to So-Young International Inc.***

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB217.1 million (US$31.0 million), compared with a non-GAAP net loss attributable to So-Young International Inc. of RMB4.7 million in fiscal year 2024.

***Basic and Diluted Loss per ADS***

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB2.39 (US$0.34) and RMB2.39 (US$0.34), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.72 and RMB5.72 in fiscal year 2024.

***Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments***

As of December 31, 2025, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB936.4 million (US$133.9 million), compared with RMB1,253.2 million as of December 31, 2024, primarily due to an increase of investment in branded aesthetic centers.

**Business Outlook**

For the first quarter of 2026, So-Young expects aesthetic treatment services revenues to be between RMB268.0 million (US$38.3 million) and RMB278.0 million (US$39.8 million), representing a 171.2% to 181.3% increase from the same period in 2025. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

**Non-GAAP Financial Measures**

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and long-lived assets from income/(loss) from operations, and excluding share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments from net income/(loss) attributable to So-Young International Inc., respectively. Starting from the fourth quarter of 2024, the Company newly included impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments as additional adjustments in its non-GAAP financial measures, which may result in differences from previously disclosed non-GAAP figures.

The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses (i) that are not expected to result in cash payments or (ii) that are non-recurring in nature or may not be indicative of the Company's core operating results and business outlook. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses, the impairment of goodwill and long-lived assets, impairment of long-term investment and allowance for credit loss from loans to investees are non-cash in nature. Gain/(loss) on disposal of long-term investment and fair value change of long-term investment are non-recurring in nature. And, in substance, both impairment of long-term investment and allowance for credit loss from loans to investees are impairment of investment. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

**Conference Call Information**

So-Young's management will hold an earnings conference call on Wednesday, March 25, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

---

| | |
|:---|:---|
| International: | +1-412-902-4272 |
| Mainland China： | 4001-201203 |
| US: | +1-888-346-8982 |
| Hong Kong： | +852-800-905-945 |
| Passcode: | So Young |

---

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, April 1, 2026. The dial-in details are:

International: +1-412-317-0088 <br> US: +1-855-669-9658 <br> Passcode: 5232304

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

**About So-Young International Inc.**

So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.

**Safe Harbor Statement**

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

**For more information, please contact:**

So-Young

Investor Relations

Ms. Mona Qiao

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

Christensen

Ms. Charlie Chi

Phone: +86-10-5900-1548

E-mail: sy@christensencomms.com

**SO-YOUNG INTERNATIONAL INC.**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Amounts in thousands, except for share and per share data)**

---

| | | | |
|:---|:---|:---|:---|
|  | **As of** | **As of** | **As of** |
|  | **December 31,**<br>**2024** | **December 31,**<br>**2025** | **December 31,**<br>**2025** |
|  | **RMB** | **RMB** | **US$** |
| **Assets** |  |  |  |
| Current assets: |  |  |  |
| Cash and cash equivalents | 587749 | 418213 | 59804 |
| Restricted cash and term deposits | 66367 | 64683 | 9250 |
| Trade receivables | 98774 | 51532 | 7369 |
| Inventories | 151754 | 233389 | 33374 |
| Receivables from online payment platforms | 24255 | 16296 | 2330 |
| Amounts due from related parties | 1218 | 774 | 111 |
| Term deposits and short-term investments | 599041 | 453472 | 64846 |
| Prepayment and other current assets | 195202 | 246237 | 35211 |
| **Total current assets** | **1724360** | **1484596** | **212295** |
| Non-current assets: |  |  |  |
| Long-term investments | 280281 | 274753 | 39289 |
| Intangible assets | 126615 | 144097 | 20606 |
| Goodwill | 684 | 684 | 98 |
| Property and equipment, net | 155352 | 293560 | 41979 |
| Deferred tax assets | 84950 | 69313 | 9912 |
| Operating lease right-of-use assets | 162764 | 251635 | 35983 |
| Other non-current assets | 200152 | 130998 | 18732 |
| **Total non-current assets** | **1010798** | **1165040** | **166599** |
| **Total assets** | **2735158** | **2649636** | **378894** |
| **Liabilities** |  |  |  |
| Current liabilities: |  |  |  |
| Short-term borrowings | 69771 | 39814 | 5693 |
| Taxes payable | 61862 | 43461 | 6215 |
| Contract liabilities | 76579 | 65948 | 9430 |
| Salary and welfare payables | 111396 | 130170 | 18614 |
| Amounts due to related parties | 477 | 618 | 88 |
| Accrued expenses and other current liabilities | 265216 | 427507 | 61134 |
| Operating lease liabilities-current | 44905 | 76536 | 10945 |
| **Total current liabilities** | **630206** | **784054** | **112119** |
| Non-current liabilities: |  |  |  |
| Operating lease liabilities-non current | 125200 | 183364 | 26221 |
| Deferred tax liabilities | 19758 | 10615 | 1518 |
| Other non-current liabilities | 1264 | 2783 | 398 |
| **Total non-current liabilities** | **146222** | **196762** | **28137** |
| **Total liabilities** | **776428** | **980816** | **140256** |

---

**SO-YOUNG INTERNATIONAL INC.**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)**

**(Amounts in thousands, except for share and per share data)**

---

| | | | |
|:---|:---|:---|:---|
| **Shareholders' equity:** | | | |
| Treasury stock | (376690) | (391944) | (56047) |
| Class A ordinary shares (US$0.0005 par value; 750,000,000 shares authorized as of December 31, 2024 and December 31, 2025; 77,897,969 and 65,659,510 shares issued and outstanding as of December 31, 2024, 79,016,808 and 65,089,482 shares issued and outstanding as of December 31, 2025, respectively) | 253 | 257 | 37 |
| Class B ordinary shares (US$0.0005 par value; 20,000,000 shares authorized as of December 31, 2024 and December 31, 2025; 12,000,000 shares issued and outstanding as of December 31, 2024 and December 31, 2025) | 37 | 37 | 5 |
| Additional paid-in capital | 3069799 | 3059764 | 437540 |
| Statutory reserves | 40552 | 46448 | 6642 |
| Accumulated deficit | (926390) | (1174587) | (167964) |
| Accumulated other comprehensive income | 31560 | 13340 | 1908 |
| **Total So-Young International Inc. shareholders' equity** | **1839121** | **1553315** | **222121** |
| Non-controlling interests | 119609 | 115505 | 16517 |
| **Total shareholders' equity** | **1958730** | **1668820** | **238638** |
| **Total liabilities and shareholders' equity** | **2735158** | **2649636** | **378894** |

---

**SO-YOUNG INTERNATIONAL INC.**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Amounts in thousands, except for share and per share data)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Three Months Ended** | **For the Fiscal Year Ended** | **For the Fiscal Year Ended** | **For the Fiscal Year Ended** |
|  | **December 31, 2024** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2025** | **December 31, 2025** |
|  | **RMB** | **RMB** | **US$** | **RMB** | **RMB** | **US$** |
| **Revenues:** |  |  |  |  |  |  |
| Aesthetic treatment services | 81267 | 248076 | 35474 | 169263 | 674903 | 96510 |
| Information and reservation services | 171624 | 125675 | 17971 | 736607 | 499685 | 71454 |
| Sales of medical products and maintenance services | 86432 | 69257 | 9904 | 367980 | 267839 | 38300 |
| Other services | 29888 | 17714 | 2533 | 192848 | 80983 | 11580 |
| **Total revenues** | **369211** | **460722** | **65882** | **1466698** | **1523410** | **217844** |
| **Cost of revenues:** |  |  |  |  |  |  |
| Cost of aesthetic treatment services | (65208) | (189017) | (27029) | (131580) | (518749) | (74180) |
| Cost of information and reservation services | (20384) | (10071) | (1440) | (106958) | (62970) | (9005) |
| Cost of medical products sold and maintenance services | (43325) | (41595) | (5948) | (183164) | (147110) | (21036) |
| Cost of other services | (24134) | (15265) | (2183) | (145883) | (66894) | (9566) |
| **Total cost of revenues** | **(153051)** | **(255948)** | **(36600)** | **(567585)** | **(795723)** | **(113787)** |
| **Gross profit** | **216160** | **204774** | **29282** | **899113** | **727687** | **104057** |
| **Operating expenses:** |  |  |  |  |  |  |
| Sales and marketing expenses | (134045) | (168678) | (24121) | (494493) | (528591) | (75588) |
| General and administrative expenses | (98420) | (101893) | (14571) | (324073) | (328523) | (46978) |
| Research and development expenses | (42753) | (37436) | (5353) | (165030) | (137040) | (19596) |
| Impairment of goodwill and long-lived assets | (540009) | (19710) | (2818) | (540009) | (19710) | (2818) |
| **Total operating expenses** | **(815227)** | **(327717)** | **(46863)** | **(1523605)** | **(1013864)** | **(144980)** |
| **Loss from operations** | **(599067)** | **(122943)** | **(17581)** | **(624492)** | **(286177)** | **(40923)** |
| **Other income/(expenses):** |  |  |  |  |  |  |
| Investment income, net | 7623 | 773 | 111 | 11020 | 1738 | 249 |
| Interest income, net | 8237 | 3453 | 494 | 46507 | 23556 | 3368 |
| Exchange (losses)/gains | (763) | 2929 | 419 | 112 | 5948 | 851 |
| Impairment of long-term investment | (7350) |  |  | (7350) |  |  |
| Share of losses of equity method investee | (3413) | (616) | (88) | (15015) | (4076) | (583) |
| Others, net | (11103) | 1670 | 238 | 1131 | 12902 | 1845 |
| **Loss before tax** | **(605836)** | **(114734)** | **(16407)** | **(588087)** | **(246109)** | **(35193)** |
| Income tax (expenses)/benefits | (2126) | 619 | 89 | 905 | (796) | (114) |
| **Net loss** | **(607962)** | **(114115)** | **(16318)** | **(587182)** | **(246905)** | **(35307)** |
| Net loss/(income) attributable to noncontrolling interests | 386 | 5266 | 753 | (2345) | 4604 | 658 |
| **Net loss attributable to So-Young International Inc.** | **(607576)** | **(108849)** | **(15565)** | **(589527)** | **(242301)** | **(34649)** |

---

**SO-YOUNG INTERNATIONAL INC.**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)**

**(Amounts in thousands, except for share and per share data)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Three Months Ended** | **For the Fiscal Year Ended** | **For the Fiscal Year Ended** | **For the Fiscal Year Ended** |
|  | **December 31, 2024** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2025** | **December 31, 2025** |
|  | **RMB** | **RMB** | **US$** | **RMB** | **RMB** | **US$** |
| **Net loss per ordinary share** | | | | | | |
| Net loss per ordinary share attributable to ordinary shareholder - basic | (7.70) | (1.40) | (0.20) | (7.43) | (3.11) | (0.44) |
| Net loss per ordinary share attributable to ordinary shareholder - diluted | (7.70) | (1.40) | (0.20) | (7.43) | (3.11) | (0.44) |
| Net loss per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares) | (5.92) | (1.08) | (0.15) | (5.72) | (2.39) | (0.34) |
| Net loss per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares) | (5.92) | (1.08) | (0.15) | (5.72) | (2.39) | (0.34) |
| Weighted average number of ordinary shares used in computing loss per share, basic\* | 78905617 | 77593230 | 77593230 | 79384454 | 77863698 | 77863698 |
| Weighted average number of ordinary shares used in computing loss per share, diluted\* | 78905617 | 77593230 | 77593230 | 79384454 | 77863698 | 77863698 |
| **Share-based compensation expenses included in:** |  |  |  |  |  |  |
| Cost of revenues | (34) | 4 | 1 | (289) | (185) | (26) |
| Sales and marketing expenses | (239) | 30 | 4 | (659) | (835) | (119) |
| General and administrative expenses | (1731) | 771 | 110 | (29527) | (7118) | (1018) |
| Research and development expenses | (211) | 66 | 9 | (2180) | (780) | (112) |

---

\* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

**SO-YOUNG INTERNATIONAL INC.**

**Reconciliation of GAAP and Non-GAAP Results**

**(Amounts in thousands, except for share and per share data)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Three Months Ended** | **For the Fiscal Year Ended** | **For the Fiscal Year Ended** | **For the Fiscal Year Ended** |
|  | **December 31, 2024** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2025** | **December 31, 2025** |
|  | **RMB** | **RMB** | **US$** | **RMB** | **RMB** | **US$** |
| **GAAP loss from operations** | **(599067)** | **(122943)** | **(17581)** | **(624492)** | **(286177)** | **(40923)** |
| Add back: Share-based compensation expenses | 2215 | (871) | (124) | 32655 | 8918 | 1275 |
| Add back: Impairment of goodwill and long-lived assets | 540009 | 19710 | 2818 | 540009 | 19710 | 2818 |
| **Non-GAAP loss from operations** | **(56843)** | **(104104)** | **(14887)** | **(51828)** | **(257549)** | **(36830)** |
| **GAAP net loss attributable to So-Young International Inc.** | **(607576)** | **(108849)** | **(15565)** | **(589527)** | **(242301)** | **(34649)** |
| Add back: Share-based compensation expenses | 2215 | (871) | (124) | 32655 | 8918 | 1275 |
| Add back: Impairment of goodwill and long-lived assets attributable to So-Young International Inc. | 540009 | 18782 | 2818 | 540009 | 18782 | 2686 |
| Add back: Impairment of long-term investment attributable to So-Young International Inc. | 7350 |  |  | 7350 |  |  |
| Add back: Allowance for credit loss from loans to investees attributable to So-Young International Inc. | 13843 |  |  | 13843 |  |  |
| Reversal: Gain on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc. | (7791) |  |  | (7791) |  |  |
| Reversal: Tax effects on non-GAAP adjustments <sup>(1)</sup> | (1276) | (2483) | (355) | (1276) | (2483) | (355) |
| **Non-GAAP net loss attributable to So-Young International Inc.** | **(53226)** | **(93421)** | **(13226)** | **(4737)** | **(217084)** | **(31043)** |

---

(1) To adjust the income tax effects of non-GAAP adjustments, which is primarily related to allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment, fair value change of long-term investment and impairment of long-lived assets. Other non-GAAP adjustment items have no tax effect, because full valuation allowances were provided for related deferred tax assets as it is more-likely-than-not they will not be realized.